Locally advanced rectal adenocarcinoma: Are preoperative short and long course radiotherapy truly equivalent?

Margalit,Ofer; Mamtani,Ronac; Lawrence,Yaacov R.; Yang,Yu‑Xiao; Baruch,Erez N.; Reiss,Kim A.; Golan,Talia; Halpern,Naama; Aderka,Dan; Giantonio,Bruce; Shacham‑Shmueli,Einat; Boursi,Ben

doi:10.3892/mco.2019.1825

Locally advanced rectal adenocarcinoma: Are preoperative short and long course radiotherapy truly equivalent?

Authors:
- Ofer Margalit
- Ronac Mamtani
- Yaacov R. Lawrence
- Yu‑Xiao Yang
- Erez N. Baruch
- Kim A. Reiss
- Talia Golan
- Naama Halpern
- Dan Aderka
- Bruce Giantonio
- Einat Shacham‑Shmueli
- Ben Boursi
View Affiliations

Affiliations: Department of Oncology, Sheba Medical Center, Tel‑Hashomer 52621, Israel, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA, Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
Published online on: March 14, 2019 https://doi.org/10.3892/mco.2019.1825
Pages: 555-559

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In the neoadjuvant treatment of locally advanced rectal adenocarcinoma, long‑ and short‑course radiotherapy are considered to be of equivalent efficacy based upon several randomized trials. The present study assessed the effect of radiotherapy dose on overall survival. Using the National Cancer Database (2006‑2013) 458 individuals with clinical stage II/III rectal adenocarcinoma treated were identified, with either short‑ (25 Gy) or long‑ (45 or 50.4 Gy) course neoadjuvant radiotherapy followed by surgery, without neoadjuvant or adjuvant chemotherapy. Multivariate COX regression was employed to evaluate differences in overall survival according to radiotherapy regimen. An association with improved overall survival in individuals treated with long‑ compared with short‑course radiotherapy was demonstrated (HR=0.50, 0.34‑0.73). The 30‑ and 90‑day post‑surgery mortality rates were higher in the short‑course group when compared with the long‑course group (12.2 vs. 2.4%; and 18.5 vs. 5.4%, respectively). Following the exclusion of patients that succumbed within 90‑days post‑surgery, overall survival advantage in the long‑course group compared with the short‑course group was maintained [hazard ratio (HR)=0.62, 0.39‑0.99], with a median overall survival of 25.3 months (IQR 16.9‑41.6) for the short‑course group compared with 43.5 months (IQR 25.6‑67.9) for the long‑course group. To the best of our knowledge, the present results suggest for the first time that long‑course radiotherapy is associated with an improved overall survival compared with short‑course radiotherapy in locally advanced rectal adenocarcinoma in the absence of chemotherapy usage. This possible advantage is clinically relevant mainly in patients who cannot tolerate systemic chemotherapy.

View Figures

View References

1	Cammà C, Giunta M, Fiorica F, Pagliaro L, Craxì A and Cottone M: Preoperative radiotherapy for resectable rectal cancer: A meta-analysis. JAMA. 284:1008–1015. 2000. View Article : Google Scholar : PubMed/NCBI
2	Colorectal Cancer Collaborative Group, : Adjuvant radiotherapy for rectal cancer: A systematic overview of 8,507 patients from 22 randomised trials. Lancet. 358:1291–1304. 2001. View Article : Google Scholar : PubMed/NCBI
3	Birgisson H, Påhlman L, Gunnarsson U and Glimelius B; Swedish Rectal Cancer Trial Group, : Adverse effects of preoperative radiation therapy for rectal cancer: Long-term follow-up of the Swedish Rectal Cancer Trial. J Clin Oncol. 23:8697–8705. 2005. View Article : Google Scholar : PubMed/NCBI
4	Marijnen CA, Kapiteijn E, van de Velde CJ, Martijn H, Steup WH, Wiggers T, Kranenbarg EK and Leer JW; Cooperative Investigators of the Dutch Colorectal Cancer Group, : Acute side effects and complications after short-term preoperative radiotherapy combined with total mesorectal excision in primary rectal cancer: Report of a multicenter randomized trial. J Clin Oncol. 20:817–825. 2002. View Article : Google Scholar : PubMed/NCBI
5	Sebag-Montefiore D, Stephens RJ, Steele R, Monson J, Grieve R, Khanna S, Quirke P, Couture J, de Metz C, Myint AS, et al: Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): A multicentre, randomised trial. Lancet. 373:811–820. 2009. View Article : Google Scholar : PubMed/NCBI
6	Park JH, Yoon SM, Yu CS, Kim JH, Kim TW and Kim JC: Randomized phase 3 trial comparing preoperative and postoperative chemoradiotherapy with capecitabine for locally advanced rectal cancer. Cancer. 117:3703–3712. 2011. View Article : Google Scholar : PubMed/NCBI
7	Roh MS, Colangelo LH, O'Connell MJ, Yothers G, Deutsch M, Allegra CJ, Kahlenberg MS, Baez-Diaz L, Ursiny CS, Petrelli NJ, et al: Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol. 27:5124–5130. 2009. View Article : Google Scholar : PubMed/NCBI
8	Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, Becker H, Raab HR, Villanueva MT, Witzigmann H, et al: Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: Results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 30:1926–1933. 2012. View Article : Google Scholar : PubMed/NCBI
9	Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A and Ollier JC; EORTC Radiotherapy Group Trial 22921, : Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 355:1114–1123. 2006. View Article : Google Scholar : PubMed/NCBI
10	McCarthy K, Pearson K, Fulton R and Hewitt J: Pre-operative chemoradiation for non-metastatic locally advanced rectal cancer. Cochrane Database Syst Rev. 12:CD0083682012.PubMed/NCBI
11	Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M and Kryj M: Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg. 93:1215–1223. 2006. View Article : Google Scholar : PubMed/NCBI
12	Ngan SY, Burmeister B, Fisher RJ, Solomon M, Goldstein D, Joseph D, Ackland SP, Schache D, McClure B, McLachlan SA, et al: Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol. 30:3827–3833. 2012. View Article : Google Scholar : PubMed/NCBI
13	Erlandsson J, Holm T, Pettersson D, Berglund Å, Cedermark B, Radu C, Johansson H, Machado M, Hjern F, Hallböök O, et al: Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): A multicentre, randomised, non-blinded, phase 3, non-inferiority trial. Lancet Oncol. 18:336–346. 2017. View Article : Google Scholar : PubMed/NCBI
14	Winchester DP, Stewart AK, Bura C and Jones RS: The National Cancer Data Base: A clinical surveillance and quality improvement tool. J Surg Oncol. 85:1–3. 2004. View Article : Google Scholar : PubMed/NCBI
15	Charlson ME, Pompei P, Ales KL and MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 40:373–383. 1987. View Article : Google Scholar : PubMed/NCBI
16	Deyo RA, Cherkin DC and Ciol MA: Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 45:613–619. 1992. View Article : Google Scholar : PubMed/NCBI